Core Points - BillionToOne, Inc. successfully closed its upsized initial public offering (IPO) of 5,233,765 shares of Class A common stock at a public offering price of $60.00 per share, resulting in gross proceeds of approximately $314.0 million before deductions [1] - The IPO included the full exercise of the underwriters' option to purchase an additional 682,665 shares [1] - The company's Class A common stock began trading on the Nasdaq Global Select Market under the ticker symbol "BLLN" on November 6, 2025 [1] Company Overview - BillionToOne is a molecular diagnostics company headquartered in Menlo Park, California, focused on creating powerful and accurate tests that are accessible to all [4] - The company utilizes a patented technology called Quantitative Counting Templates™ (QCT™), which is the only multiplex technology capable of accurately counting DNA molecules at the single-molecule level [4] Offering Details - The registration statement related to the securities was filed with the U.S. Securities and Exchange Commission and became effective on November 5, 2025 [2] - A prospectus describing the terms of the offering has been filed with the SEC and is available on their website [2]

Core Viewpoint - Shares of BillionToOne (BLLN) have doubled on their opening day of trading, indicating strong investor optimism regarding the company's innovative technology for disease detection from a single drop of blood [1] Group 1: Company Overview - BillionToOne has developed a revolutionary technology aimed at detecting diseases, which has garnered significant attention from investors [1] Group 2: Market Reaction - The stock price of BillionToOne experienced a doubling on its first trading day, reflecting a positive market sentiment and high expectations for the company's future prospects [1]

Core Insights - Three companies, Evommune, BillionToOne, and Grupo Aeroméxico, went public on November 6, raising a total of $646 million, averaging approximately $215 million per company [1] Group 1: Evommune (EVMN) - Evommune opened at $17.25, a 7.25% increase from the offering price, and closed at $20.23, marking a 26.44% rise with a total market capitalization of $608 million [2][5] - The company issued 9.38 million shares at an offering price of $16, raising $150 million [5] - Evommune focuses on innovative therapies for immune-mediated inflammatory mechanisms, projecting $3 million in revenue and a net loss of $28.12 million for the first half of 2025 [5] Group 2: BillionToOne (BLLN) - BillionToOne opened at $100, a 66.67% increase from the offering price, and closed at $108.94, reflecting an 81.57% gain with a total market capitalization of $4.795 billion [6][9] - The company issued 4.55 million shares at an offering price of $60, raising $273 million [9] - BillionToOne specializes in molecular diagnostics, developing prenatal and oncology diagnostic products through its single-molecule next-generation sequencing (smNGS) platform, with projected revenue of $126 million and a net loss of $4.23 million for the first half of 2025 [9] Group 3: Grupo Aeroméxico (AERO) - Grupo Aeroméxico opened at $19.16, a slight increase of 0.84%, and closed at $20.35, resulting in a 7.11% rise with a total market capitalization of $2.969 billion [9][11] - The company issued 11.73 million shares at an offering price of $19, raising $223 million [11] - Grupo Aeroméxico provides domestic and international flight services, covering 22 countries and 52 international cities, with projected revenue of $2.498 billion and a net profit of $89.97 million for the first half of 2025 [11]

Group 1 - BillionToOne officially listed on NASDAQ with an opening stock price surge of 81.57%, reaching a market capitalization of nearly $4.8 billion [1] - The IPO price was set at $60, with the stock opening at $100 and peaking at $123.45 during trading, indicating strong investor interest [1] - The company raised $273 million by issuing 4.55 million shares, with the offering size increased by 20% within regulatory limits [1] Group 2 - BillionToOne specializes in non-invasive prenatal testing (NIPT) and tumor blood testing based on single-molecule sequencing technology [2] - The company reported an 82% year-over-year revenue growth and a doubling of gross profit for the first half of the year, showcasing strong commercialization capabilities [2] - The successful IPO of BillionToOne is seen as a significant signal of recovery in the IPO market, particularly for high-growth medical technology companies [2]

Core Insights - BillionToOne, Inc. successfully completed an upsized initial public offering (IPO) of 4.6 million shares at $60 per share, raising approximately $273.1 million in gross proceeds [1] - The shares began trading on the Nasdaq Global Select Market on November 6, 2025, with the offering expected to close on November 7, 2025 [1] Company Representation - Gunderson Dettmer has represented BillionToOne through various financing rounds, including Series A and late-stage equity and debt private rounds, providing strategic counsel from early funding to public market entry [2] Underwriters - J.P. Morgan, Piper Sandler, Jefferies, and William Blair are acting as joint book-running managers for the IPO, with Stifel, Wells Fargo Securities, and BTIG also participating as book-running managers [3] Legal Team - The Gunderson deal team included several partners and associates specializing in corporate law and public offerings, showcasing the firm's expertise in navigating complex capital markets [4]

Group 1 - The government shutdown has impacted the IPO market, but some companies have still managed to go public [1][2] - Three companies went public on a recent Thursday, with BillionToOne being one of them [2] - BillionToOne, a molecular diagnostics company, priced its IPO at $60 per share and saw its stock nearly double to around $120 on its first trading day, resulting in a valuation of approximately $6.4 billion [3] Group 2 - BillionToOne raised $273 million from its stock sale, trading on the Nasdaq under the ticker symbol BLLN [3]

BillionToOne has become a newly minted public company, raising $273.1m in an upsized initial public offering (IPO), despite the longest government shutdown in US history hampering those wishing to join the stock exchange. The US-based company sold around 4.5 million shares of its common stock at $60 each. The molecular test developer initially offered around 3.8 million shares that were expected to fall between $49 and $55 each. BillionToOne’s IPO has given it a market valuation at around $2.6bn. The mol ...

Core Insights - Shares of BillionToOne increased by 66.67% during their Nasdaq debut, indicating strong market interest and investor confidence in the company [1] - The market valuation of BillionToOne reached $4.4 billion following the initial public offering, reflecting the company's growth potential in the molecular diagnostics sector [1] Company Summary - BillionToOne is a molecular diagnostics firm that has successfully launched its shares on Nasdaq, marking a significant milestone for the company [1] - The substantial rise in share price on debut suggests a positive reception from investors, which may enhance the company's visibility and credibility in the industry [1] Industry Context - The molecular diagnostics industry is experiencing increased investor interest, as evidenced by BillionToOne's successful IPO and significant valuation [1] - The performance of BillionToOne may indicate broader trends in the diagnostics market, where innovative companies are attracting capital and attention [1]

Core Insights - Molecular diagnostics firm BillionToOne successfully raised $273.1 million in its U.S. initial public offering (IPO) [1] - The company priced its shares above the marketed range, indicating strong investor demand [1] Company Summary - BillionToOne specializes in molecular diagnostics, a sector focused on the analysis of biological markers in the genome and proteome [1] - The successful IPO reflects the growing interest and investment in the molecular diagnostics industry [1] Financial Highlights - The total amount raised in the IPO was $273.1 million, showcasing significant capital influx for the company [1] - Pricing of shares above the marketed range suggests a positive market reception and confidence in the company's future prospects [1]

Core Insights - BillionToOne Inc. successfully raised $273.1 million in an upsized US initial public offering despite the ongoing US government shutdown, which has complicated the listing process [1][4]. Company Overview - The company, based in Menlo Park, California, sold 4.55 million shares at $60 each, exceeding the initially marketed range of $49 to $55 for 3.85 million shares [2]. - Following the IPO, BillionToOne's market value is estimated to be over $2.6 billion, with co-founders holding 64% of the voting power [3]. Financial Performance - For the six months ending June 30, BillionToOne reported a net loss of $4.2 million on revenue of $125.5 million, an improvement from a net loss of $15.2 million on revenue of $69.1 million during the same period the previous year [5]. Product Offerings - The company specializes in precision diagnostics, with its flagship product, Unity Complete, being a non-invasive prenatal screening test. Additionally, it offers NorthStar liquid biopsy tests that can detect tumor mutations [5]. Investor Information - Major investors include Hummingbird Ventures, which is expected to hold 19.9% of Class A shares post-IPO, Neotribe Ventures with 11%, and Libertus Capital with 9% [6]. - The IPO is being led by JPMorgan Chase & Co., Piper Sandler Cos., Jefferies Financial Group Inc., and William Blair & Co. The shares are expected to begin trading on the Nasdaq Global Select Market under the symbol BLLN [6].